{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-107824","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.459063+00:00","generated_at":"2026-05-31T03:57:32.677657+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akari updates Peak Bio merger conditions, CEO compensation revised, pipeline prioritization","bullets":["Merger with Peak Bio conditions include Peak Bio net cash > -$13.5M and PIPE net proceeds ≥ $10M; expected closing Q4 2024.","Post-merger combined entity to focus on Peak Bio's ADC platform and Akari's PAS-nomacopan GA program; HSCT-TMA suspended.","Interim CEO Samir Patel's monthly $50k compensation changed from shares to NQSOs with 2x ADS multiplier.","PAS-nomacopan IND filing for geographic atrophy expected in 2025; preclinical data suggests 3-month+ intravitreal dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-107824","json":"https://secwatch.observer/filing/0000950170-24-107824.json","markdown":"https://secwatch.observer/filing/0000950170-24-107824.md","text":"https://secwatch.observer/filing/0000950170-24-107824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/0000950170-24-107824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/aktx-20240913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:57:32.677657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f682da4352","claim":"Robert Bazemore was appointed as director at Akari Therapeutics Plc.","evidence_excerpt":"the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/0000950170-24-107824-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}